- Home
- PMVP vs ETON Comparison
PMVP vs ETON Comparison
Compare PMVP & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ETON
- Stock Information
- Founded
- PMVP 2013
- ETON 2017
- Country
- PMVP United States
- ETON United States
- Employees
- PMVP N/A
- ETON N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- ETON Health Care
- Exchange
- PMVP Nasdaq
- ETON Nasdaq
- Market Cap
- PMVP 85.5M
- ETON 199.5M
- IPO Year
- PMVP 2020
- ETON 2018
- Fundamental
- Price
- PMVP $1.65
- ETON $8.77
- Analyst Decision
- PMVP Strong Buy
- ETON Strong Buy
- Analyst Count
- PMVP 4
- ETON 3
- Target Price
- PMVP $5.75
- ETON $12.00
- AVG Volume (30 Days)
- PMVP 185.0K
- ETON 214.1K
- Earning Date
- PMVP 11-07-2024
- ETON 11-11-2024
- Dividend Yield
- PMVP N/A
- ETON N/A
- EPS Growth
- PMVP N/A
- ETON N/A
- EPS
- PMVP N/A
- ETON N/A
- Revenue
- PMVP N/A
- ETON $31,381,000.00
- Revenue This Year
- PMVP N/A
- ETON $19.61
- Revenue Next Year
- PMVP N/A
- ETON $35.39
- P/E Ratio
- PMVP N/A
- ETON N/A
- Revenue Growth
- PMVP N/A
- ETON 8.14
- 52 Week Low
- PMVP $1.33
- ETON $3.03
- 52 Week High
- PMVP $3.47
- ETON $8.66
- Technical
- Relative Strength Index (RSI)
- PMVP 60.86
- ETON 76.07
- Support Level
- PMVP $1.63
- ETON $7.58
- Resistance Level
- PMVP $1.69
- ETON $8.66
- Average True Range (ATR)
- PMVP 0.07
- ETON 0.42
- MACD
- PMVP 0.01
- ETON -0.07
- Stochastic Oscillator
- PMVP 52.65
- ETON 91.49
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.